Loading the security overview…
Where the tokens are
| Quarter | Reported | EPS | EPS vs year ago | Revenue | Revenue vs year ago | Consensus EPS |
|---|---|---|---|---|---|---|
| Q2 FY26ended Jun 30, 2026 | Aug 4, 2026 | $4.37 | +64.9% | $10.05B | +9.5% | $5.62 |
| Q1 FY26ended Mar 31, 2026 | May 7, 2026 | $3.34 | +4.4% | $8.62B | +5.8% | $4.74 |
| Q4 FY25ended Dec 31, 2025 | — | $2.45 | +113.0% | $9.87B | +8.6% | — |
| Q3 FY25ended Sep 30, 2025 | — | $5.93 | +13.6% | $9.56B | +12.4% | — |
| Q2 FY25ended Jun 30, 2025 | — | $2.65 | +92.0% | $9.18B | +9.4% | — |
| Q1 FY25ended Mar 31, 2025 | — | $3.20 | — | $8.15B | +9.4% | — |
| Q4 FY24ended Dec 31, 2024 | — | $1.15 | −19.0% | $9.09B | +10.9% | — |
| Q3 FY24ended Sep 30, 2024 | — | $5.22 | +62.1% | $8.50B | +23.2% |
Growth compares each quarter with the same fiscal quarter a year earlier, and is left blank where that quarter is missing or its figure was zero or a loss. Consensus is the estimate published before each report. It usually refers to adjusted EPS, so it is shown beside the GAAP figure rather than subtracted from it: the difference would not be a beat or a miss.
Figures describe Amgen shares, not any token. As of Aug 4, 2026, from Massive's standardised financials and the earnings calendar.
| — |
| Q2 FY24ended Jun 30, 2024 | — | $1.38 | — | $8.39B | — | — |
| Q1 FY24ended Mar 31, 2024 | — | −$0.21 | — | $7.45B | — | — |
| Q4 FY23ended Dec 31, 2023 | — | $1.42 | — | $8.20B | — | — |
| Q3 FY23ended Sep 30, 2023 | — | $3.22 | — | $6.90B | — | — |